



ASX Announcement  
Invitrocue Limited (ASX:IVQ)

## Invitrocue Bolsters Global Insurance Strategy with Appointment of Advisor

### Investment Highlights

- Appointed Dato Dr Sharifuddin Abdul Wahab as Global Insurance Advisor
- Dato Dr Wahab will advise and support Invitrocue's global insurance strategy which seeks to establish a framework which will enable more patients to have access to Invitrocue's Onco-PDO service
- Dato Dr Wahab is a Chairman Board of Commissioners of KSK Insurance Indonesia, one of the region's largest insurance companies

06 May, 2019: Innovative life sciences company **Invitrocue Limited (ASX: IVQ)**, (**'Invitrocue' or 'the Company'**), is pleased to announce the appointment of Dr Sharifuddin Abdul Wahab as Global Insurance Advisor.

In his role at Invitrocue, Dato Dr Wahab will advise and support the Company's global insurance strategy for its Onco Patient-Derived Organoid ('Onco-PDO') service.

Dato Dr Wahab is a Veterinary doctor by training who has extensive experience in the commercial sector. He is a Chairman Board of Commissioners of KSK Insurance Indonesia, one of the region's largest insurance companies. Prior to this, he held a number of roles at Schmidt Scientific including CEO of Schmidt BioMedTech Asia.

Whereas many cancer treatments today are "one-size-fits-all", Invitrocue's Onco-PDO service takes a personalised approach and allows physicians to prescribe the most appropriate treatment regime for the particular patient.

At present, most cancer treatments are expensive and inefficient. Invitrocue envisages a future in which patients can receive subsidies from insurers rather than paying out of pocket to access the Company's Onco-PDO service that will eliminate to a large degree the guesswork from cancer treatment. Dato Dr Wahab will provide guidance and advice on a global insurance strategy to achieve this.

"Dato" is an honorary title bestowed upon Malaysians who have made significant contributions to their nation.

**Dr Steven Fang, CEO of Invitrocue, said:** "We are very pleased to welcome Dato Dr Wahab to the team as an advisor. Dato Dr Wahab is a well-respected and leading expert in the insurance field, and we believe his vast experience will bring important insights to our global insurance strategy. With his assistance, Invitrocue is paving the way to a future in which more patients will have access to personalized cancer treatment that will lead to better patient outcomes."



**Dato Dr Sharifuddin Abdul Wahab, Advisor at Invitrocue, said:** “It is a true privilege to be appointed as an advisor at a company doing such exciting work. Invitrocue has created a truly innovative personalised approach to cancer treatment and I am looking forward to provide guidance on the Company’s global insurance strategy to allow more cancer patients to benefit from their service.”

**For further information, please contact:**

**Invitrocue**

**Martin D. Bach**

VP Operations

M: +65 6460 0497

E: [martind.bach@invitrocue.com](mailto:martind.bach@invitrocue.com)

**Media & Investor Enquiries**

**Julia Maguire**

The Capital Network

M: +61 419 815 386

E: [julia@thecapitalnetwork.com.au](mailto:julia@thecapitalnetwork.com.au)

**[www.invitrocue.com](http://www.invitrocue.com)**

**About Invitrocue (ASX:IVQ)**

Invitrocue Limited (ASX:IVQ) is an innovative life sciences company that specialises in developing ground-breaking 3D cell-based models derived from liver and tumour tissues.

Headquartered in Singapore and with operations in Australia, China, Hong Kong and Germany, Invitrocue’s Onco-PDO technology enables patient-derived cancer cells (organoids) to be cultured in laboratories for testing against a panel of drugs to support personalised clinical decisions.

By enabling assessments of the best ways for drugs to be developed, Invitrocue creates better, faster and more affordable disease treatments, that work towards the company’s goal of creating a healthier society.

To learn more, please visit: [www.invitrocue.com](http://www.invitrocue.com)

**About KSK Group**

KSK Group Berhad, formerly known as Kurnia Asia Berhad, was incorporated on 16 February 2001. KSK Group is an investment holding company with a vision to be a diversified conglomerate. The Group's current core business is general insurance and it was also the previous owner that has built Kurnia Insurans (Malaysia) Berhad ("KIMB") into Malaysia's largest homegrown general insurance company with gross premium exceeding RM1 billion. After the disposal of KIMB, the Group currently focuses on growing its two general insurance operations in Indonesia and Thailand.

For personal use only